CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Clinical trials for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE explained in plain language.
Never miss a new study
Get alerted when new CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE trials appear
Sign up with your email to follow new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a common cholesterol drug slow blood cancer?
Disease control Recruiting nowThis study tests whether statins, a common cholesterol-lowering drug, can help people with early blood disorders called CCUS and lower-risk MDS. These conditions can progress to more serious blood cancers, and there are no approved treatments to prevent that. The study will measu…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 03:41 UTC
-
Vitamin c boost: could high doses make chemo more effective for tough lymphomas?
Disease control Recruiting nowThis phase 2 trial tests whether adding high-dose intravenous vitamin C to standard chemotherapy can help treat blood cancers like lymphoma that have returned or not responded to treatment, as well as related conditions. About 80 adults will receive the combination to see if it i…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:41 UTC
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis study tests a drug called olutasidenib in 15 people with specific blood conditions (CCUS, lower-risk MDS, or CMML) that have an IDH1 mutation. The goal is to see if the drug can help control the disease and to check for side effects. Participants must have a confirmed diagno…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:40 UTC
-
New drug aims to boost blood counts in rare pre-cancer condition
Disease control Recruiting nowThis study tests a drug called enasidenib in 15 people with clonal cytopenia of undetermined significance (CCUS) who have a mutation in the IDH2 gene. CCUS causes low blood cell counts and can raise the risk of blood cancers. The drug blocks the faulty protein made by the mutated…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Could early treatment stop a Pre-Cancer blood disorder?
Disease control Recruiting nowThis study looks at whether giving an oral drug early to people with a high-risk blood condition (CCUS) is safe and practical. CCUS can sometimes turn into blood cancer. Participants can choose to take the drug or just be watched. The goal is to see if early action helps control …
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: EARLY_PHASE1 • Sponsor: Lachelle D. Weeks, MD, PhD • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
Can a common inflammation blocker stop blood cancer before it starts?
Prevention Recruiting nowThis study tests whether canakinumab, a drug that reduces inflammation, can prevent blood cancer in people with CCUS—a condition where blood counts are low and certain gene mutations raise cancer risk. About 110 adults with high-risk CCUS will receive either canakinumab or a plac…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Prevention
Last updated May 22, 2026 14:01 UTC
-
Turmeric compound tested for blood disorder symptoms
Symptom relief Recruiting nowThis study is testing whether a curcumin supplement (the active ingredient in turmeric) can lower inflammation and improve symptoms in people with certain blood disorders, including low-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). About 30 adults wi…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Symptom relief
Last updated May 19, 2026 11:48 UTC
-
Can we predict blood cancer after ovarian cancer treatment?
Knowledge-focused Recruiting nowThis study follows 2,000 people who have had ovarian or other solid cancers to understand why some later develop blood cancers. Researchers will look at genetic changes and treatment history to identify risk factors. The goal is to improve monitoring and prevention for cancer sur…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 26, 2026 03:37 UTC
-
10-Year study tracks hidden DNA changes that could lead to blood cancer
Knowledge-focused Recruiting nowThis study follows 306 adults with CHIP or CCUS—conditions where DNA changes in blood cells raise the risk of blood cancers or heart disease. Over 10 years, researchers will track participants with yearly check-ups, blood tests, and scans to see how these changes evolve. The goal…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC
-
Can a simple genetic test catch blood cancers before they start?
Knowledge-focused Recruiting nowThis study uses advanced genetic testing (next generation sequencing) to look for early warning signs of pre-myeloid cancers and bone marrow failure in 2000 people. Participants have certain blood abnormalities or genetic markers that may increase their risk. The goal is to bette…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 18, 2026 12:07 UTC